Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness — Live Feedhttps://www.live-feeds.com/feed/makers-of-glp-1-drugs-ordered-to-add-warnings-about-rare-eye-condition-that-can-lead-to-blindnessContinuously updated, source-cited coverage. FDA orders blindness warning on GLP-1 drugs including Ozempic, Wegovy, Zepboundhttps://www.live-feeds.com/feed/makers-of-glp-1-drugs-ordered-to-add-warnings-about-rare-eye-condition-that-can-lead-to-blindnesshttps://www.live-feeds.com/feed/makers-of-glp-1-drugs-ordered-to-add-warnings-about-rare-eye-condition-that-can-lead-to-blindness#u199802Sat, 14 Nov 2026 03:17:05 +0000The U.S. Food and Drug Administration has ordered manufacturers of popular GLP-1 diabetes and weight-loss drugs to add warnings about a rare eye condition that can cause permanent vision loss. The condition, non-arteritic anterior ischemic optic neuropathy (NAION), has been reported in patients taking semaglutide and tirzepatide products. Affected brands include Ozempic, Wegovy, Rybelsus, Zepbound, and Mounjaro. The FDA says the risk is rare but serious, and the new label language must reflect the potential for irreversible blindness.Why it mattersGLP-1 receptor agonists have become blockbuste